Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 1996

Primary Completion Date

June 30, 1996

Study Completion Date

June 30, 1996

Conditions
Reflux Oesophagitis
Interventions
DRUG

YF476

"Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:~Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth~Groups A \& B were dosed alternately, at weekly intervals"

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

Trio Medicines Ltd.

INDUSTRY